Moolec Science (MLEC) Deferred Taxes (2023 - 2024)
Moolec Science (MLEC) reported Deferred Taxes of $280889.0 for Q4 2024, up 219.03% on a YoY basis from $88045.9 in Q1 2024, and up 1103.57% sequentially from -$27989.0 in Q3 2024.
Moolec Science (MLEC) Deferred Taxes (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Deferred Taxes data on file, last reported at $280889.0 in Q4 2024.
- For the quarter ending Q4 2024, Deferred Taxes rose 219.03% year-over-year to $280889.0; the trailing twelve-month figure through Dec 2024 stood at -$342804.0 (changed N/A YoY), and the FY2024 full-year result was -$1.0 million, down 346.4% from the prior year.
- Deferred Taxes grew to $280889.0 in Q4 2024, from -$27989.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $280889.0 in Q4 2024 to a low of -$722654.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 280,889.00 |
| Sep 30, 2024 | -27,989.00 |
| Jun 30, 2024 | -722,654.00 |
| Mar 31, 2024 | 126,950.00 |
| Dec 31, 2023 | -235,990.00 |
| Sep 30, 2023 | -215,291.00 |